Actively Recruiting
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Led by Novartis Pharmaceuticals · Updated on 2025-01-14
250
Participants Needed
12
Research Sites
176 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open label, prospective, multicenter, non-comparative study to assess the safety and effectiveness of Tabrecta® (Capmatinib) in real world setting. Also, this study is to fulfill the regulatory requirements as part of the RMP (Risk Management Plan) for Tabrecta® (Capmatinib), as requested by Korea Health Authority, MFDS (Ministry of Food and Drug Safety).
CONDITIONS
Official Title
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent obtained before joining the study
- Diagnosed with exon 14 skipping mutated NSCLC confirmed by tissue or plasma (ctDNA) analysis by treating physician
- Planning to receive Tabrecta4 (Capmatinib) according to the locally approved label
You will not qualify if you...
- Contraindications to Tabrecta4 (Capmatinib) as per the locally approved label
- Medical records not accessible
- Unwilling to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Novartis Investigative Site
Daegu, Dalseo Gu, South Korea, 42602
Actively Recruiting
2
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea, 16499
Actively Recruiting
3
Novartis Investigative Site
Seoul, Korea, South Korea, 02447
Actively Recruiting
4
Novartis Investigative Site
Seoul, Seocho Gu, South Korea, 06591
Actively Recruiting
5
Novartis Investigative Site
Busan, South Korea, 602-030
Actively Recruiting
6
Novartis Investigative Site
Daejeon, South Korea, 302-241
Actively Recruiting
7
Novartis Investigative Site
Incheon, South Korea, 405 760
Actively Recruiting
8
Novartis Investigative Site
Jeollanam, South Korea, 519763
Actively Recruiting
9
Novartis Investigative Site
Seoul, South Korea, 02841
Actively Recruiting
10
Novartis Investigative Site
Seoul, South Korea, 05505
Actively Recruiting
11
Novartis Investigative Site
Seoul, South Korea, 06273
Actively Recruiting
12
Novartis Investigative Site
Seoul, South Korea, 06351
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here